Comparative Pharmacology
Head-to-head clinical analysis: ORETON METHYL versus TESTODERM TTS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORETON METHYL versus TESTODERM TTS.
ORETON METHYL vs TESTODERM TTS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
Testosterone is an androgen receptor agonist. It binds to and activates androgen receptors, leading to changes in gene expression that promote the development and maintenance of male secondary sexual characteristics, anabolic effects, and spermatogenesis.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
Apply 4 mg (one 4 mg/24 hr system) or 6 mg (one 6 mg/24 hr system) transdermally once daily, applied to clean, dry, intact skin on the back, abdomen, thighs, or upper arms. Rotate application sites with an interval of at least 7 days.
None Documented
None Documented
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
The terminal elimination half-life of testosterone administered transdermally is approximately 1.5–2 hours. This short half-life requires daily application of the patch to maintain therapeutic levels.
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Testosterone is excreted primarily in the urine as glucuronide and sulfate conjugates (approximately 90%), with about 6% excreted in feces via bile. Less than 1% is excreted unchanged.
Category C
Category C
Androgen
Androgen